COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022

We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kislaya, Irina, Machado, Ausenda, Magalhães, Sarah, Rodrigues, Ana Paula, Franco, Rafael, Leite, Pedro Pinto, Dias, Carlos Matias, Nunes, Baltazar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479470/
https://www.ncbi.nlm.nih.gov/pubmed/36111555
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.37.2200697
_version_ 1784790798198374400
author Kislaya, Irina
Machado, Ausenda
Magalhães, Sarah
Rodrigues, Ana Paula
Franco, Rafael
Leite, Pedro Pinto
Dias, Carlos Matias
Nunes, Baltazar
author_facet Kislaya, Irina
Machado, Ausenda
Magalhães, Sarah
Rodrigues, Ana Paula
Franco, Rafael
Leite, Pedro Pinto
Dias, Carlos Matias
Nunes, Baltazar
author_sort Kislaya, Irina
collection PubMed
description We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in ≥ 80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.
format Online
Article
Text
id pubmed-9479470
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-94794702022-10-03 COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022 Kislaya, Irina Machado, Ausenda Magalhães, Sarah Rodrigues, Ana Paula Franco, Rafael Leite, Pedro Pinto Dias, Carlos Matias Nunes, Baltazar Euro Surveill Rapid Communication We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in ≥ 80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death. European Centre for Disease Prevention and Control (ECDC) 2022-09-15 /pmc/articles/PMC9479470/ /pubmed/36111555 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.37.2200697 Text en This article is copyright of the authors or their affiliated institutions, 2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Kislaya, Irina
Machado, Ausenda
Magalhães, Sarah
Rodrigues, Ana Paula
Franco, Rafael
Leite, Pedro Pinto
Dias, Carlos Matias
Nunes, Baltazar
COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
title COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
title_full COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
title_fullStr COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
title_full_unstemmed COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
title_short COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
title_sort covid-19 mrna vaccine effectiveness (second and first booster dose) against hospitalisation and death during omicron ba.5 circulation: cohort study based on electronic health records, portugal, may to july 2022
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479470/
https://www.ncbi.nlm.nih.gov/pubmed/36111555
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.37.2200697
work_keys_str_mv AT kislayairina covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022
AT machadoausenda covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022
AT magalhaessarah covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022
AT rodriguesanapaula covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022
AT francorafael covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022
AT leitepedropinto covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022
AT diascarlosmatias covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022
AT nunesbaltazar covid19mrnavaccineeffectivenesssecondandfirstboosterdoseagainsthospitalisationanddeathduringomicronba5circulationcohortstudybasedonelectronichealthrecordsportugalmaytojuly2022

Ejemplares similares